Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the
assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.